百克生物：公司在研的阿尔茨海默病治疗性疫苗正处于临床前研究阶段

Core Viewpoint - The company is developing an Alzheimer's disease therapeutic vaccine targeting Aβ and Tau proteins, aiming to induce the body to produce antibodies to clear pathological Aβ and Tau proteins in the brain, thereby slowing disease progression. The project is currently in the preclinical research stage [2]. Group 1 - The therapeutic vaccine is designed based on internationally recognized antigens targeting Aβ and Tau proteins [2]. - The goal of the vaccine is to stimulate the immune system to produce antibodies against Aβ and Tau [2]. - The project is still in the preclinical research phase, indicating it has not yet entered clinical trials [2].